These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
201 related articles for article (PubMed ID: 21631272)
1. p63 expression in giant cell-containing lesions of bone and soft tissue. de la Roza G Arch Pathol Lab Med; 2011 Jun; 135(6):776-9. PubMed ID: 21631272 [TBL] [Abstract][Full Text] [Related]
2. P63 expression as a biomarker discriminating giant cell tumor of bone from other giant cell-rich bone lesions. Shooshtarizadeh T; Rahimi M; Movahedinia S Pathol Res Pract; 2016 Oct; 212(10):876-879. PubMed ID: 27473669 [TBL] [Abstract][Full Text] [Related]
3. Giant cell tumor of bone express p63. Dickson BC; Li SQ; Wunder JS; Ferguson PC; Eslami B; Werier JA; Turcotte RE; Kandel RA Mod Pathol; 2008 Apr; 21(4):369-75. PubMed ID: 18311114 [TBL] [Abstract][Full Text] [Related]
4. Can p63 serve as a biomarker for giant cell tumor of bone? A Moroccan experience. Hammas N; Laila C; Youssef AL; Hind el F; Harmouch T; Siham T; Afaf A Diagn Pathol; 2012 Sep; 7():130. PubMed ID: 23016917 [TBL] [Abstract][Full Text] [Related]
5. Immunohistochemical analysis of 36 cases of chondroblastomas: A single institutional experience. Rekhi B; Ghate S; Shah A; Ramadwar M; Gulia A Ann Diagn Pathol; 2020 Feb; 44():151440. PubMed ID: 31862519 [TBL] [Abstract][Full Text] [Related]
6. Gene expression profiling identifies p63 as a diagnostic marker for giant cell tumor of the bone. Lee CH; Espinosa I; Jensen KC; Subramanian S; Zhu SX; Varma S; Montgomery KD; Nielsen TO; van de Rijn M; West RB Mod Pathol; 2008 May; 21(5):531-9. PubMed ID: 18192965 [TBL] [Abstract][Full Text] [Related]
7. Soft-tissue and bone tumors about the foot and ankle. Walling AK; Gasser SI Clin Sports Med; 1994 Oct; 13(4):909-38. PubMed ID: 7805113 [TBL] [Abstract][Full Text] [Related]
8. Utility of P63 in Differentiating Giant Cell Tumor from Other Giant Cell-Containing Lesions. Hui M; Uppin SG; Kumar KK; Radhika S; Chandrasekhar P; Rao KN Turk Patoloji Derg; 2022; 38(1):9-15. PubMed ID: 34514571 [TBL] [Abstract][Full Text] [Related]
9. A diagnosis of giant cell-rich tumour of bone is supported by p63 immunohistochemistry, when more than 50 % of cells is stained. Maues De Paula A; Vasiljevic A; Giorgi R; Gomez-Brouchet A; Aubert S; Leroy X; Duval H; de Pinieux G; Bouvier C Virchows Arch; 2014 Oct; 465(4):487-94. PubMed ID: 25100342 [TBL] [Abstract][Full Text] [Related]
10. Immunohistochemical evaluation of microphthalmia-associated transcription factor expression in giant cell lesions. Seethala RR; Goldblum JR; Hicks DG; Lehman M; Khurana JS; Pasha TL; Zhang PJ Mod Pathol; 2004 Dec; 17(12):1491-6. PubMed ID: 15205688 [TBL] [Abstract][Full Text] [Related]
11. L-type amino acid transporter-1 and CD98 expression in bone and soft tissue tumors. Koshi H; Sano T; Handa T; Yanagawa T; Saitou K; Nagamori S; Kanai Y; Takagishi K; Oyama T Pathol Int; 2015 Sep; 65(9):460-7. PubMed ID: 26134029 [TBL] [Abstract][Full Text] [Related]
12. Immunohistochemistry for histone H3G34W and H3K36M is highly specific for giant cell tumor of bone and chondroblastoma, respectively, in FNA and core needle biopsy. Schaefer IM; Fletcher JA; Nielsen GP; Shih AR; Ferrone ML; Hornick JL; Qian X Cancer Cytopathol; 2018 Aug; 126(8):552-566. PubMed ID: 29757500 [TBL] [Abstract][Full Text] [Related]
13. RANK signalling in bone lesions with osteoclast-like giant cells. Won KY; Kalil RK; Kim YW; Park YK Pathology; 2011 Jun; 43(4):318-21. PubMed ID: 21532526 [TBL] [Abstract][Full Text] [Related]
14. SATB2 is a novel marker of osteoblastic differentiation in bone and soft tissue tumours. Conner JR; Hornick JL Histopathology; 2013 Jul; 63(1):36-49. PubMed ID: 23701429 [TBL] [Abstract][Full Text] [Related]
16. [Expression of H3.3 G34W mutant-specific antibody in giant cell tumors of bone and its diagnostic value]. Wang X; Wu N; Zhang RS; Wei X; Ji RH; Ma HH; Zhou XJ; Rao Q Zhonghua Bing Li Xue Za Zhi; 2020 Feb; 49(2):116-121. PubMed ID: 32074722 [No Abstract] [Full Text] [Related]
17. Is Core Needle Biopsy Reliable in Differentiating Between Aggressive Benign and Malignant Radiolucent Bone Tumors? Hegde V; Burke ZDC; Park HY; Zoller SD; Johansen D; Kelley BV; Levine B; Motamedi K; Federman NC; Seeger LL; Nelson SD; Bernthal NM Clin Orthop Relat Res; 2018 Mar; 476(3):568-577. PubMed ID: 29529643 [TBL] [Abstract][Full Text] [Related]
18. Mutation Analysis of H3F3A and H3F3B as a Diagnostic Tool for Giant Cell Tumor of Bone and Chondroblastoma. Cleven AH; Höcker S; Briaire-de Bruijn I; Szuhai K; Cleton-Jansen AM; Bovée JV Am J Surg Pathol; 2015 Nov; 39(11):1576-83. PubMed ID: 26457357 [TBL] [Abstract][Full Text] [Related]
19. p63 immunohistochemical staining is limited in soft tissue tumors. Jo VY; Fletcher CD Am J Clin Pathol; 2011 Nov; 136(5):762-6. PubMed ID: 22031315 [TBL] [Abstract][Full Text] [Related]
20. [Benign and malignant giant-cell rich lesions of bone: Pathological diagnosis with special emphasis on recent immunohistochemistry and molecular techniques]. Macagno N; Caselles K; Aubert S; Audard V; Gomez-Brouchet A; Galant C; Guinebretière JM; Karanian M; Larousserie F; Marie B; de Pinieux G; Bouvier C Ann Pathol; 2018 Apr; 38(2):92-102. PubMed ID: 29580573 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]